Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor

Background: Patients with Crohn’s disease suffer from intestinal bile acid malabsorption. Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). In rats, ASBT is induced by glucocorticoids. Aims: To study whether human ASBT is activated...

Full description

Saved in:
Bibliographic Details
Published inGut Vol. 53; no. 1; pp. 78 - 84
Main Authors Jung, D, Fantin, A C, Scheurer, U, Fried, M, Kullak-Ublick, G A
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and British Society of Gastroenterology 01.01.2004
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Copyright 2004 by Gut
Subjects
Online AccessGet full text
ISSN0017-5749
1468-3288
1458-3288
DOI10.1136/gut.53.1.78

Cover

More Information
Summary:Background: Patients with Crohn’s disease suffer from intestinal bile acid malabsorption. Intestinal bile acid absorption is mediated by the apical sodium dependent bile acid transporter ASBT/IBAT (SLC10A2). In rats, ASBT is induced by glucocorticoids. Aims: To study whether human ASBT is activated by glucocorticoids and to elucidate the mechanism of regulation. Patients and methods: ASBT expression in ileal biopsies from patients with Crohn’s disease and from healthy subjects was quantified by western blot. ASBT promoter function was studied in luciferase assays and by electrophoretic mobility shift assay. Results: In 16 patients with Crohn’s disease, ASBT expression was reduced to 69 (7.5)% compared with healthy controls (mean (SEM); p = 0.01). In 10 healthy male volunteers, ASBT protein expression was increased 1.34 (0.11)-fold (mean (SEM); p<0.05) after 21 days’ intake of budesonide (9 mg/day) whereas expression of the peptide transporter 1 was unaffected. Reporter constructs of the human ASBT promoter were activated 15–20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide. Two glucocorticoid response elements in the ASBT promoter, arranged as inverted hexanucleotide repeats (IR3 elements), conferred inducibility by GR and dexamethasone in a heterologous promoter context and were shown to bind GR in mobility shift assays. Conclusions: Human ASBT is induced by glucocorticoids in vitro and in vivo. Induction of ASBT by glucocorticoids could be beneficial in patients with Crohn’s disease who exhibit reduced ASBT expression. This study identifies ASBT as a novel target of glucocorticoid controlled gene regulation in the human intestine.
Bibliography:href:gutjnl-53-78.pdf
ark:/67375/NVC-PFVKRNX8-8
PMID:14684580
Correspondence to:
 Dr G A Kullak-Ublick
 Division of Gastroenterology and Hepatology, and Division of Clinical Pharmacology and Toxicology, University Hospital, CH-8091 Zurich, Switzerland; gerd.kullak@usz.ch
istex:32238588E0721561BBDAF5D8A59F5119F153266D
local:0530078
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Correspondence to: …Dr G A Kullak-Ublick …Division of Gastroenterology and Hepatology, and Division of Clinical Pharmacology and Toxicology, University Hospital, CH-8091 Zurich, Switzerland; gerd.kullak@usz.ch
D Jung and A C Fantin contributed equally to this work.
ISSN:0017-5749
1468-3288
1458-3288
DOI:10.1136/gut.53.1.78